RSLV-132 is under clinical development by Resolve Therapeutics and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase II drugs for Systemic Lupus Erythematosus have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RSLV-132’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RSLV-132 overview
RSLV-132 is under development for the treatment of post-acute sequelae of covid 2019 (PASC OR LONG COVID) and primary Sjogren's syndrome. It is administered through intravenous route as a solution. The drug candidate is a mono-specific nuclease Fc fusion protein consisting of human RNase attached to the Fc portion of human IgG. It targets toll like receptor 7 and toll like receptor 8 and is being developed based on nuclease therapy platform. It was also under treatment for systemic lupus erythematosus (SLE).
It was also under development for the treatment of subarachnoid hemorrhage.
Resolve Therapeutics overview
Resolve Therapeutics is a clinical development company that develops transformative therapies for autoimmune and post-viral illnesses. The company is headquartered in Miami, Florida, the US.
For a complete picture of RSLV-132’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
